RSS   Newsletter   Contact   Advertise with us

Novartis delivers solid performance in Q2

Staff writer ▼ | July 21, 2015
Novartis delivered solid performance in the second quarter. Net sales amounted to $12.7 billion (-5%, +6% in constant currencies, cc).
Novartis   Operating income was $2.3 billion
Operating income was $2.3 billion (-28%, -14% cc). Core operating income was $3.6 billion (-7%, +6% cc). Q2 core margin improved 0.3 percentage points (cc).

Core EPS was $1.27 (-7%, +7% cc), and free cash flow was $2.1 billion. Further strengthening of $impacted sales by -11% and core operating income by -13%. Strong performance for Sandoz (net sales +11% cc, core operating income +30% cc) and Pharmaceuticals (net sales +6% cc, core operating income +9% cc), more than offset weak quarter for Alcon (net sales 0% cc, core operating income -10% cc).

Outlook 2015 for continuing operations was confirmed: continuing operations net sales expected to grow mid-single digit (cc); core operating income expected to grow ahead of sales at a high-single digit rate (cc); to reflect first half performance, Novartis raises Sandoz FY guidance to high single digit sales growth (cc), lowers Alcon FY guidance to low single digit sales growth (cc).